Andromeda Announces Successful Interim Results of Leading Product DiaPep 227 for Treatment of Type 1 Diabetes

Published: Jun 25, 2008

Rehovot, Israel, June 23rd 2008 - Andromeda Biotech, a wholly owned subsidiary of CBI, focused on the development of innovative treatment for autoimmune diabetes, announced the successful results from the Interim Analysis of safety and efficacy data from the phase III clinical study conducted with DiaPep277, the company's lead product for the treatment of type 1 diabetes.

Back to news